The Swiss Biotech Association (SBA) held the Swiss Biotech Day in Basel on 22–23 April. Swissmedic took part in the event as a member of the SBA’s Steering Committee. At a staffed stand, the Agency showed how to best take account of the legal framework conditions and thereby facilitate access to new technologies. Because rapid access to safe, innovative therapeutic products is a major concern for Swiss patients.
Philippe Girard and Jörg Schläpfer contributed their expertise to the panel discussions “How regulators can best support innovation” and “Investments into global healthcare systems” from the perspective of the regulatory authority. They emphasised the significance of patient safety and indicated the importance of the scientific and regulatory framework conditions. In doing so, Swissmedic made an important contribution to ensuring that the Swiss biotech industry can continue to grow and consolidate Switzerland’s position as a key player at the forefront of bioscience innovation.
Through its commitment to the SBA, Swissmedic is fulfilling the Federal Council’s requirements. The strategic objectives include, among other things, actively supporting the development of innovative therapeutic products and facilitating rapid access to innovative treatments for patients in Switzerland.
The Swiss Biotech Report 2023 was presented at the event. It shows the current status of the Swiss biotech industry (framework conditions, facts and figures, and outlook).